We have located links that may give you full text access.
Predictors of One Year Compliance with Adaptive Servo-Ventilation in Patients with Heart Failure and Sleep- Disordered Breathing: Preliminary Data from the ADVENT-HF Trial.
European Respiratory Journal 2018 November 9
Peak flow-targeted adaptive servo ventilation (ASVpf) suppresses both obstructive (OSA) and central sleep apnoea (CSA). Although high hours of positive airway pressure (PAP) use improves quality of life, long-term compliance is problematic. We evaluated ASVpf use in patients with heart failure and reduced ejection fraction with either OSA or CSA to determine the short and long-term predictors of ASV pf compliance.Of 177 patients randomised to ASVpf, compliance data were available at one and 12 months post-randomisation in 91 with OSA and 45 with CSA. Among patients with OSA, ASVpf use was 4.6 [2.9] h per day at one month but decreased to 4.1 [4.7] h at 12 months (p=0.04). Among patients with CSA, median ASVpf use was 5.2 [4.0] h per day at one month and 5.2 [3.5] h per day at 12 months (p=0.52). The only predictor of ASVpf use at 12 months was hours of use at one month (OR 2.02: CI 1.58-2.60, p<0.01).These data indicate better compliance with ASVpf than previously reported for other PAP devices in patients with cardiovascular diseases. Hours of daily use at one month predicted compliance at 12 months, indicating that if good short-term compliance is achieved, this effect can be sustained long-term.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app